HANSOH PHARMA's candidate drug HX111 has completed the first patient dosing
HANSOH PHARMA - B (03378.HK) announced that the company has initiated a Phase I clinical trial for its independently developed candidate drug HX111 (a candidate drug targeting OX40 antibody conjugate) for relapsed refractory lymphoma and solid tumors, successfully completing the first patient enrollment and dosing recently
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments